Popular Trials
Cancer Vaccine
Cancer Vaccine + Sargramostim for Breast Cancer or alternatively, Cancer Vaccine + Sargramostim for Ovarian Cancer
Recruiting1 awardPhase 1
Seattle, Washington
This trial is testing a new treatment for advanced breast and ovarian cancer. The treatment helps the body's defense system recognize and attack cancer cells, while another component increases the number of defense cells. Researchers aim to find the safest dose and see if it effectively triggers the body's defense system. This type of treatment has shown promise in previous studies for its safety and ability to stimulate the body's defense system.
Popular Filters
Trials for Brain Tumor Patients
MEK Inhibitor
MEKTOVI for Pediatric Craniopharyngioma
Recruiting1 awardPhase 2
Aurora, Colorado
This trial tests MEKTOVI, a pill that targets cancer growth proteins, in children and young adults with a recurring brain tumor called Adamantinomatous Craniopharyngioma. The drug works by blocking signals that make cancer cells grow.
IL-6 receptor antagonist
ACTEMRA for Pediatric Craniopharyngioma
Recruiting1 awardPhase 2
Aurora, Colorado
This trial tests ACTEMRA, a drug that blocks a protein called IL-6, in children with a recurring brain tumor called ACP. The goal is to see if it can reduce tumor growth and improve their quality of life.
Kinase Inhibitor
Vemurafenib + Cobimetinib for Craniopharyngioma
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial tests vemurafenib and cobimetinib to treat patients with a certain type of brain tumor. The drugs may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Platinum-containing Compound
Chemotherapy and Stem Cell Transplant for Germ Cell Cancer
Recruiting2 awardsPhase 3
La Jolla, California
This study is evaluating whether a combination of chemotherapy and a stem cell transplant is more effective than chemotherapy alone in treating patients with germ cell tumors.
Trials for Brain Stem Glioma Patients
MEK Inhibitor
MEKTOVI for Pediatric Craniopharyngioma
Recruiting1 awardPhase 2
Aurora, Colorado
This trial tests MEKTOVI, a pill that targets cancer growth proteins, in children and young adults with a recurring brain tumor called Adamantinomatous Craniopharyngioma. The drug works by blocking signals that make cancer cells grow.
IL-6 receptor antagonist
ACTEMRA for Pediatric Craniopharyngioma
Recruiting1 awardPhase 2
Aurora, Colorado
This trial tests ACTEMRA, a drug that blocks a protein called IL-6, in children with a recurring brain tumor called ACP. The goal is to see if it can reduce tumor growth and improve their quality of life.
Kinase Inhibitor
Vemurafenib + Cobimetinib for Craniopharyngioma
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial tests vemurafenib and cobimetinib to treat patients with a certain type of brain tumor. The drugs may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Platinum-containing Compound
Chemotherapy and Stem Cell Transplant for Germ Cell Cancer
Recruiting2 awardsPhase 3
La Jolla, California
This study is evaluating whether a combination of chemotherapy and a stem cell transplant is more effective than chemotherapy alone in treating patients with germ cell tumors.
Trials With No Placebo
MEK Inhibitor
MEKTOVI for Pediatric Craniopharyngioma
Recruiting1 awardPhase 2
Aurora, Colorado
This trial tests MEKTOVI, a pill that targets cancer growth proteins, in children and young adults with a recurring brain tumor called Adamantinomatous Craniopharyngioma. The drug works by blocking signals that make cancer cells grow.
IL-6 receptor antagonist
ACTEMRA for Pediatric Craniopharyngioma
Recruiting1 awardPhase 2
Aurora, Colorado
This trial tests ACTEMRA, a drug that blocks a protein called IL-6, in children with a recurring brain tumor called ACP. The goal is to see if it can reduce tumor growth and improve their quality of life.
Monoclonal Antibodies
Tocilizumab for Craniopharyngioma
Recruiting1 awardPhase < 1
Aurora, Colorado
This trial tests if tocilizumab, an anti-inflammatory drug, can reach and affect brain tumors in patients with craniopharyngioma. If successful, patients will receive the drug regularly over several months to see if it helps control their tumors.
Kinase Inhibitor
Vemurafenib + Cobimetinib for Craniopharyngioma
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial tests vemurafenib and cobimetinib to treat patients with a certain type of brain tumor. The drugs may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.